Sektion Klinische Infektiologie, Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität München, Pettenkoferstraße 8a, 80336, Munich, Germany.
Klinik für Gastroenterologie, Klinikum Dritter Orden München-Nymphenburg, Menzinger Straße 44, 80638, Munich, Germany.
Infection. 2016 Oct;44(5):641-9. doi: 10.1007/s15010-016-0911-1. Epub 2016 Jun 2.
The aim of this cross-sectional study was to evaluate the prevalence and risk factors of medium-grade proteinuria (100-500 mg/g creatinine) among HIV-positive adults.
Spot urine samples of HIV-positive adults without known renal disease were analyzed quantitatively between January 2009 and February 2011. Demographic and medical data were collected. Multivariate regression models for different patterns of proteinuria were constructed.
Among 411 patients, 18 (4.4 %) presented albuminuria >300 mg/g creatinine and/or proteinuria >500 mg/g creatinine and were excluded from further analyses. Among the study population of 393 patients, 181 (46.1 %) had no significant proteinuria or albuminuria (<100 and <30 mg/g creatinine, respectively), 60 (15.3 %) had moderate albuminuria, while 152 (38.7 %) had proteinuria without albuminuria, suggesting tubular proteinuria. Independent predictors for medium-grade tubular proteinuria in multivariate analysis were exposure to tenofovir (DF), a CD4 nadir <500/µl, older age, and anti-HCV-antibodies. There was no association with classic renal risk factors like diabetes mellitus and arterial hypertension, or with estimated glomerular filtration rate (eGFR).
We detected significant proteinuria in 230 (56.0 %) of 411 HIV-positive patients. Among this group, 152 (66.1 %) had medium-grade proteinuria without albuminuria, which was significantly associated with exposure to tenofovir, older age, a lower CD4 nadir and Hepatitis C. Nephrologic or HIV treatment guidelines fail to detect most of these patients but rather identify patients with high cardiovascular risk. In the absence of an association with eGFR the role of medium-grade tubular proteinuria as a potential early marker of chronic kidney disease remains unclear. Prospective studies are needed.
本横断面研究旨在评估 HIV 阳性成年人中中等级蛋白尿(100-500mg/g 肌酐)的患病率和危险因素。
2009 年 1 月至 2011 年 2 月间,对无已知肾脏疾病的 HIV 阳性成年人进行定量分析点尿样。收集人口统计学和医学数据。构建不同蛋白尿模式的多变量回归模型。
在 411 名患者中,18 名(4.4%)出现白蛋白尿>300mg/g 肌酐和/或蛋白尿>500mg/g 肌酐,因此被排除在进一步分析之外。在 393 名研究人群中,181 名(46.1%)无明显蛋白尿或白蛋白尿(分别<100 和<30mg/g 肌酐),60 名(15.3%)有中度白蛋白尿,152 名(38.7%)有蛋白尿而无白蛋白尿,提示肾小管性蛋白尿。多变量分析中,中等级肾小管性蛋白尿的独立预测因子是使用替诺福韦(DF)、CD4 最低点<500/µl、年龄较大和抗 HCV 抗体。与经典的肾脏危险因素如糖尿病和高血压,或估算的肾小球滤过率(eGFR)没有关联。
我们在 411 名 HIV 阳性患者中检测到显著蛋白尿的患者有 230 名(56.0%)。在这一组中,152 名(66.1%)有中等级蛋白尿而无白蛋白尿,这与使用替诺福韦、年龄较大、CD4 最低点较低和丙型肝炎显著相关。肾脏或 HIV 治疗指南无法检测到大多数这些患者,而是识别出有高心血管风险的患者。由于与 eGFR 没有关联,中等级肾小管性蛋白尿作为慢性肾脏病的潜在早期标志物的作用仍不清楚。需要前瞻性研究。